

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. LUD 5501 US
		First Inventor Jean-Christophe Renaud
		Title ASTHMA ASSOCIATED FACTORS AS, etc.
		Express Mail Label No. 11002061813

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>		Box Patent Application ADDRESS TO: Commissioner for Patents Washington, DC 20231
--	--	---

1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original, and a duplicate for fee processing)</small>	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (<i>Appendix</i>)
2. <input checked="" type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27.	8. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small>
3. <input checked="" type="checkbox"/> Specification [Total Pages 46] <small>(preferred arrangement set forth below)</small> - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (<i>if filed</i>) - Detailed Description - Claim(s) - Abstract of the Disclosure	a. <input type="checkbox"/> Computer Readable Form (CRF)
4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 22]	b. <input type="checkbox"/> Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies), or ii. <input checked="" type="checkbox"/> paper
5. Oath or Declaration a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 18 completed)</small> i. <input type="checkbox"/> DELETION OF INVENTOR(S) <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)</small>	c. <input checked="" type="checkbox"/> Statements verifying identity of above copies
6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76	10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small>
<input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: 09/157,247	11. <input type="checkbox"/> English Translation Document (<i>if applicable</i>)
Prior application information: Examiner E. Urban Group / Art Unit: 1642	12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.	

19. CORRESPONDENCE ADDRESS				
<input type="checkbox"/> Customer Number or Bar Code Label		or <input checked="" type="checkbox"/> Correspondence address below		
Name	FULBRIGHT & JAWORSKI L.L.P. Mary Anne Schofield			
Address	Market Square 801 Pennsylvania Avenue, N.W.			
City	Washington	State	DC	Zip Code 20004-2615
Country	US	Telephone	(202) 662-0200	Fax (202) 662-4643

Name (Print/Type)	Mary Anne Schofield	Registration No. (Attorney/Agent)	36,669
Signature	<i>Mary Anne Schofield</i>		Date February 8, 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 830.00

Complete if Known

Application Number	Not yet assigned
Filing Date	Concurrently herewith
First Named Inventor	Jean-Christophe Renaud
Examiner Name	N/A
Group Art Unit	N/A
Attorney Docket No.	LUD 5501.1 CON. US

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None
 Deposit Account

Deposit Account Number 06-2375

Deposit Account Name Fulbright & Jaworski L.L.P.

The Commissioner is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	370.00
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	
SUBTOTAL (1) (\$)				370.00	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims	Fee from below	Fee Paid
Total Claims	25	-20** =	5 x 9.00 =	45.00
Independent Claims	8	-3** =	5 x 42.00 =	210.00
Multiple Dependent				

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$)				255.00

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	460.00
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	
Other fee (specify)					
*Reduced by Basic Filing Fee Paid				SUBTOTAL (3) (\$)	0.00

SUBMITTED BY *Complete if applicable*

Name (Print/Type) Mary Anne Schofield Registration No. 36,669 Telephone (202) 662-4584

Signature *Mary Anne Schofield* Date February 8, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jean-Christophe Renaud

Application No.: Not yet assigned Group Art Unit: Not yet assigned

Filed: Concurrently herewith Examiner: Not yet assigned

For: ASTHMA ASSOCIATED FACTORS AS
TARGETS FOR TREATING ATOPIC
ALLERGIES INCLUDING ASTHMA AND
RELATED DISORDERS

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed are the following items for filing in connection with the above-referenced
Design Patent Application:

1. Fee Transmittal
2. Continuation Patent Application Transmittal
3. Petition for three-month extension of time
4. Preliminary Amendment
5. Specification (46 pages) and Figures 1-22 (22 sheets)
6. Declaration
7. Associate Power of Attorney
8. Statement Claiming Small Entity
9. Statement Pursuant to 37 C.F.R. 1.821 (f) and (g)
10. Request to Transfer the CRF (Disk)
11. Sequence Listing
12. Check in the amount of \$830.00 to cover filing fee.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375.

Dated: February 8, 2002

Respectfully submitted,

By Mary Anne Schofield
Mary Anne Schofield
Registration No. 36,669

FULBRIGHT & JAWORSKI L.L.P.
Market Square
801 Pennsylvania Avenue, N.W.
Washington, DC 20004-2604
(202) 662-0200

Docket No.: LUD 5501.1 CON. US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jean-Christophe Renauld

Application No.: Not yet assigned

Group Art Unit: N/A

Filed: Concurrently herewith

Examiner: N/A

For: ASTHMA ASSOCIATED FACTORS AS
TARGETS FOR TREATING ATOPIC
ALLERGIES INCLUDING ASTHMA AND
RELATED DISORDERS

STATEMENT PURSUANT TO 37 CFR 1.821 (f) and (g)

Box Sequence

Commissioner for Patents
Washington, DC 20231

Dear Sir:

The undersigned hereby declares that:

1. I am an attorney registered to practice before the U.S. Patent and Trademark Office. My Registration No. is 36,669.
2. Pursuant to 37 C.F.R. § 1.821(f), the content of the paper copy required by § 1.821(c) is the same as that in the computer readable form required by § 1.821(e), submitted December 17, 1999 in application Serial No. 09/468,433.
3. Pursuant to 37 C.F.R. § 1.821(g), the submitted Sequence Listing in both paper copy form and computer readable form contain no new matter.

Respectfully submitted,

Dated: February 8, 2002

By *Mary Anne Schofield*
Mary Anne Schofield
Registration No.: 36,669

FULBRIGHT & JAWORSKI L.L.P.
801 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 662-0200

Docket No.: LUD 5501.1 CON. US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jean-Christophe Renaud

Application No.: Not yet assigned Group Art Unit: N/A

Filed: Concurrently herewith Examiner: N/A

For: ASTHMA ASSOCIATED FACTORS AS
TARGETS FOR TREATING ATOPIC
ALLERGIES INCLUDING ASTHMA AND
RELATED DISORDERS

REQUEST TO TRANSFER THE CRF (DISK)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Applicants submit concurrently herewith a paper copy of a sequence listing reciting the appropriate information in this application, a Statement Under § 1.821 (f) and (g) and a request to have the CRF from the prior application, Serial No. 09/157,247, transferred to this file.

Dated: February 8, 2002

Respectfully submitted,

By *Mary Anne Schofield*
Mary Anne Schofield
Registration No.: 36,669

FULBRIGHT & JAWORSKI L.L.P.
Market Square
801 Pennsylvania Avenue, N.W.
Washington, DC 20004-2604
(202) 662-4584
Attorneys for Applicant